Skip to main content

Market Overview

Cytokinetics Still A Buy After Phase 2 SMA Data

Cytokinetics Still A Buy After Phase 2 SMA Data

Data presented by Cytokinetics, Inc. (NASDAQ: CYTK) showed CK-107 has the ability to positively impact two different animal models of spinal muscular atrophy.

Rodman & Renshaw’s Joseph Pantginis reiterated a Buy rating on the company, with a price target of $25.

Positive Indications

The analyst mentioned the animal models for CK-107 mimic both adult-onset and intermediate iterations of SMA, with both experiments revealing statistically significant impact on muscular force improvement.

Pantginis believes the data presented is “important in supporting the underlying mechanism of action for CK-107.”

Phase 2 Study

Following this preclinical data, Cytokinetics is scheduled to report data on its Phase 2 SMA study in mid-2017.

“Regarding expectations, this is not a typical black and white Phase 2 study with definitive endpoints. Rather it is geared toward generating hypothesis based on the experimental endpoints in the study in order to help define next steps,” the analyst explained.

The endpoints are meant to assess several metrics associated with muscle function and fatigability, with Pantginis believing the preliminary data suggests these measures would be important for the path ahead.

Following recent approvals for SMA drugs by other pharma companies, the analyst expressed optimism CK-107 had “significant potential” to “work in a complementary manner to these therapies and should not be viewed in a competitive fashion.”

Other Data

Cytokinetics also announced additional positive data from its COSMIC-HF study at the ACC 2017, with the data revealing the first echocardiographic evidence omecamtiv mecarbil might have a statistically significant positive impact on left ventricular, myocardial deformation, one of the factors associated with outcomes in heart failure patients.

Related Link:

Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference

Teva's Stock Inches Higher Amid Cost-Cutting Plan

Latest Ratings for CYTK

Mar 2021Wolfe ResearchInitiates Coverage OnOutperform
Jan 2021HC Wainwright & Co.MaintainsBuy
Dec 2020Morgan StanleyMaintainsOverweight

View More Analyst Ratings for CYTK
View the Latest Analyst Ratings


Related Articles (CYTK)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Reiteration FDA Analyst Ratings Best of Benzinga

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at